Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › valproate

valproate

9 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of valproate

36 trials tracked of valproate: 16 in phase 3 or 4 and 4 with published results. The most-cited published study has 636 citations.

36Trials tracked
16Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 7 Phase 3 9 Phase 2 12 Phase 1 3 Other / NA 5
  1. Phase 3 Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study Completed · 636 cited
  2. Phase 3 Established Status Epilepticus Treatment Trial Completed · 90 cited
  3. Phase 4 Cost- Effectiveness and Quality of Life Assessment in Mood Disorder Completed · 6 cited
  4. Phase 4 Gabapentin for Alcohol Withdrawal Syndrome Completed · 4 cited
  5. Phase 4 Effect of Valproic Acid Concentration on Photic Response Completed
  6. Phase 4 Valproate Versus Ketorolac Versus Metoclopramide Completed
Show 30 more trials
  1. Phase 4 Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures Completed
  2. Phase 4 Valproate in Late Life Schizophrenia Completed
  3. Phase 4 Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation Completed
  4. Phase 3 Treatment Strategy for Alcohol Use Disorders in Veterans With TBI Completed
  5. Phase 3 Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine. Completed
  6. Phase 3 Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder Completed
  7. Phase 3 Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar Completed
  8. Phase 3 Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents Completed
  9. Phase 3 Valproate in Dementia (VALID) Completed
  10. Phase 3 Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder Completed
  11. Phase 2 Valproate Efficacy in Cocaine-Bipolar Comorbidity Completed
  12. Phase 2 Trial of Oral Valproic Acid for Retinitis Pigmentosa Completed
  13. Phase 2 A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin Completed
  14. Phase 2 Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism Completed
  15. Phase 2 Phase II 5-Azacytidine Plus VPA Plus ATRA Completed
  16. Phase 2 Valproic Acid for the Prevention of Post-Amputation Pain Completed
  17. Phase 2 Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma Completed
  18. Phase 2 PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS Completed
  19. Phase 2 Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors Completed
  20. Phase 2 Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) Completed
  21. Phase 2 Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma Completed
  22. Phase 2 Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS) Completed
  23. Phase 1 Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions Completed
  24. Phase 1 Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study Completed
  25. Phase 1 Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions Completed
  26. N/A Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening Completed
  27. N/A Bipolar Disorder in Late Life Completed
  28. N/A Determining Metabolic Effects of Valproate and Antipsychotic Therapy Completed
  29. N/A Decision-Making in Bipolar Disorder Completed
  30. N/A Valproate for Mood Swings and Alcohol Use Following Head Injury Completed

Showing the 36 most-cited and recently-updated of 36 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review and meta-analysis of mood stabilizers for nonsuicidal self-injury in adolescents
Psychiatry Meta-analysis
Systematic review and meta-analysis of mood stabilizers for nonsuicidal self-injury in adolescents Mood stabilizers show promise for teen self-injury and depression in China
This systematic review and meta-analysis examined nine studies from China involving adolescent patients with nonsuicidal self-injury. The au…
A review of nine studies suggests mood stabilizers may help reduce self-injury and depression in Chinese adolescents, offering new options f…
May 20, 2026
Predictive nomogram identifies suboptimal valproate concentrations in pediatric epilepsy patients using daily dose, organ injury, and meropenem
Drug Pipeline Cohort
Predictive nomogram identifies suboptimal valproate concentrations in pediatric epilepsy patients using daily dose, organ injury, and meropenem New tool predicts dangerous valproate levels in children with epilepsy
This retrospective cohort study of 121 pediatric patients with epilepsy aged 2–18 years developed a predictive nomogram to identify suboptim…
A new calculator can flag children with epilepsy who are likely to get unsafe valproate levels, helping doctors adjust doses before problems…
Frontiers Apr 24, 2026
FDA Approves Valproic Acid Oral Solution (valproic acid) for Complex Partial and Absence Seizures
Neurology FDA Approval
FDA Approves Valproic Acid Oral Solution (valproic acid) for Complex Partial and Absence Seizures The FDA has approved a liquid form of an older seizure medicine called valproic acid
Valproic acid oral solution is approved as monotherapy and adjunctive therapy for complex partial seizures and for simple and complex absenc…
The FDA approved a liquid version of valproic acid to help adults and children over 10 manage complex partial and absence seizures when pill…
FDA Apr 7, 2026
FDA Approves Valproic Acid Oral Solution (valproic acid) for Monotherapy and Adjunctive Therapy of Complex Partial and Absence Seizures
Neurology FDA Approval
FDA Approves Valproic Acid Oral Solution (valproic acid) for Monotherapy and Adjunctive Therapy of Complex Partial and Absence Seizures FDA approves a liquid form of an existing epilepsy medicine called valproic acid
The FDA has approved valproic acid oral solution for monotherapy and adjunctive therapy of complex partial seizures, and as sole and adjunct…
FDA approves liquid valproic acid for epilepsy patients 10 and older who struggle to swallow pills or need flexible dosing.
FDA Apr 7, 2026
FDA Approves Valproic Acid Oral Solution (valproic acid) for Monotherapy and Adjunctive Therapy of Complex Partial and Absence Seizures
Neurology FDA Approval
FDA Approves Valproic Acid Oral Solution (valproic acid) for Monotherapy and Adjunctive Therapy of Complex Partial and Absence Seizures The FDA has approved a liquid form of an existing epilepsy and migraine prevention medicine
The FDA has approved valproic acid oral solution for monotherapy and adjunctive therapy of complex partial seizures, and as sole and adjunct…
The FDA approved a liquid version of valproic acid, an established epilepsy and migraine medicine, offering an easier swallowing option for …
FDA Apr 7, 2026
FDA Approves Depakote (divalproex sodium) for Manic Episodes Associated with Bipolar Disorder
Neurology FDA Approval
FDA Approves Depakote (divalproex sodium) for Manic Episodes Associated with Bipolar Disorder FDA approves Depakote for treating manic episodes in bipolar disorder
The FDA approved Depakote (divalproex sodium) for the treatment of manic episodes associated with bipolar disorder.
FDA approves Depakote for treating manic episodes in hospitalized adults with bipolar disorder, offering doctors a new option for managing a…
FDA Apr 2, 2026
FDA Approves Depakote ER (divalproex sodium) for Acute Manic or Mixed Episodes in Bipolar Disorder
Neurology FDA Approval
FDA Approves Depakote ER (divalproex sodium) for Acute Manic or Mixed Episodes in Bipolar Disorder FDA approves a new once-daily pill for treating manic episodes in bipolar disorder
The FDA has approved Depakote ER, an extended-release valproate, for the acute treatment of manic or mixed episodes associated with bipolar …
FDA approves a new once-daily pill for short-term treatment of severe manic episodes in adults with bipolar I disorder.
FDA Apr 2, 2026
FDA Approves Valproate Sodium Injection (valproate sodium) for IV Use in Complex Partial and Absence Seizures
Neurology FDA Approval
FDA Approves Valproate Sodium Injection (valproate sodium) for IV Use in Complex Partial and Absence Seizures FDA approves an injectable version of an existing seizure medicine for short-term use
The FDA approved Valproate Sodium Injection as an intravenous alternative when oral valproate is temporarily not feasible.
FDA approves an injectable seizure medicine for short-term use when patients can't swallow pills due to surgery or stomach issues.
FDA Apr 2, 2026
FDA Approves Depakote Sprinkle Capsules (valproate) for Monotherapy and Adjunctive Therapy of Complex Partial and Absence Seizures
Neurology FDA Approval
FDA Approves Depakote Sprinkle Capsules (valproate) for Monotherapy and Adjunctive Therapy of Complex Partial and Absence Seizures FDA approves a new sprinkle capsule form of the epilepsy drug Depakote
The FDA approved Depakote Sprinkle Capsules (valproate) for monotherapy and adjunctive therapy of complex partial seizures and simple and co…
FDA approves a sprinkle capsule form of Depakote that patients can open and mix with soft food to help those who struggle to swallow pills.
FDA Apr 2, 2026